|
1
|
Eguchi H, Kobayashi S, Gotoh K, Noda T and
Doki Y: Characteristics of early-onset pancreatic cancer and its
association with familial pancreatic cancer and hereditary
pancreatic cancer syndromes. Ann Gastroenterol Surg. 4:229–233.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moore A and Donahue T: Pancreatic cancer.
JAMA. 322:14262019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shibata H, Komura S, Yamada Y, Sankoda N,
Tanaka A, Ukai T, Kabata M, Sakurai S, Kuze B, Woltjen K, et al: In
vivo reprogramming drives Kras-induced cancer development. Nat
Commun. 9:20812018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo J: KRAS mutation in pancreatic cancer.
Semin Oncol. 48:10–18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of Larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang L, Guo Z, Wang F and Fu L: KRAS
mutation: From undruggable to druggable in cancer. Signal Transduct
Target Ther. 6:3862021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haigis KM: KRAS alleles: The devil is in
the detail. Trends Cancer. 3:686–697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Windon AL, Loaiza-Bonilla A, Jensen CE,
Randall M, Morrissette JJD and Shroff SG: A KRAS wild type
mutational status confers a survival advantage in pancreatic ductal
adenocarcinoma. J Gastrointest Oncol. 9:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambrogio C, Kohler J, Zhou ZW, Wang H,
Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, et al: KRAS
dimerization impacts MEK inhibitor sensitivity and oncogenic
activity of mutant KRAS. Cell. 172:857–868. e152018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kent OA: Increased mutant KRAS gene dosage
drives pancreatic cancer progression: Evidence for wild-type KRAS
as a tumor suppressor? Hepatobiliary Surg Nutr. 7:403–405. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perets R, Greenberg O, Shentzer T,
Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E and
Hershkovitz D: Mutant KRAS circulating tumor DNA is an accurate
tool for pancreatic cancer monitoring. Oncologist. 23:566–572.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hobbs GA, Baker NM, Miermont AM, Thurman
RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B,
et al: Atypical KRASG12R mutant is impaired in PI3K
signaling and macropinocytosis in pancreatic cancer. Cancer Discov.
10:104–123. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mueller S, Engleitner T, Maresch R,
Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R,
Zwiebel M, Strong A, et al: Evolutionary routes and KRAS dosage
define pancreatic cancer phenotypes. Nature. 554:62–68. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santamaria PG, Moreno-Bueno G, Portillo F
and Cano A: EMT: Present and future in clinical oncology. Mol
Oncol. 11:718–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Georgakopoulos-Soares I, Chartoumpekis DV,
Kyriazopoulou V and Zaravinos A: EMT factors and metabolic pathways
in cancer. Front Oncol. 10:4992020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sommariva M and Gagliano N: E-Cadherin in
pancreatic ductal adenocarcinoma: A multifaceted actor during EMT.
Cells. 9:10402020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The E-Cadherin and
N-Cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications and challenges. Cells.
8:11182019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Christgen M, Bartels S, van Luttikhuizen
JL, Bublitz J, Rieger LU, Christgen H, Stark H, Sander B, Lehmann
U, Steinemann D, et al: E-cadherin to P-cadherin switching in
lobular breast cancer with tubular elements. Mod Pathol.
33:2483–2498. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang B, Li X, Liu L and Wang M: β-Catenin:
Oncogenic role and therapeutic target in cervical cancer. Biol Res.
53:332020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu XP, Pokutta S, Torres M, Swift MF,
Hanein D, Volkmann N and Weis WI: Structural basis of
αE-catenin-F-actin catch bond behavior. Elife. 9:e608782020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Terekhova K, Pokutta S, Kee YS, Li J,
Tajkhorshid E, Fuller G, Dunn AR and Weis WI: Binding partner- and
force-promoted changes in αE-catenin conformation probed by native
cysteine labeling. Sci Rep. 9:153752019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rogers CD, Sorrells LK and Bronner ME: A
catenin-dependent balance between N-cadherin and E-cadherin
controls neuroectodermal cell fate choices. Mech Dev. 152:44–56.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ryu WJ, Han G, Lee SH and Choi KY:
Suppression of Wnt/β-catenin and RAS/ERK pathways provides a
therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Biochem Biophys Res Commun. 549:40–46. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kelppe J, Thoren H, Haglund C, Sorsa T and
Hagstrom J: MMP-7, −8, −9, E-cadherin and beta-catenin expression
in 34 ameloblastoma cases. Clin Exp Dent Res. 7:63–69. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, He J, Wang F, Wang X, Yang F, Zhao
C, Feng C and Li T: Role of MMP-9 in epithelial-mesenchymal
transition of thyroid cancer. World J Surg Oncol. 18:1812020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao Y, Qiao X, Wang L, Tan TK, Zhao H,
Zhang Y, Zhang J, Rao P, Cao Q, Wang Y, et al: Matrix
metalloproteinase 9 induces endothelial-mesenchymal transition via
Notch activation in human kidney glomerular endothelial cells. BMC
Cell Biol. 17:212016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liutkevicius V, Lesauskaite V,
Liutkeviciene R, Vaiciulis P and Uloza V: Matrix Metalloproteinases
(MMP-2,-3,-9) Gene polymorphisms in cases of benign vocal fold
lesions and laryngeal carcinoma. In Vivo. 34:267–274. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suhaimi SA, Chan SC and Rosli R: Matrix
Metallopeptidase 3 Polymorphisms: Emerging genetic markers in human
breast cancer metastasis. J Breast Cancer. 23:1–9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen XK, Gu CL, Fan JQ and Zhang XM:
P-STAT3 and IL-17 in tumor tissues enhances the prognostic value of
CEA and CA125 in patients with lung adenocarcinoma. Biomed
Pharmacother. 125:1098712020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liang B, Li SY, Gong HZ, Wang LX, Lu J,
Zhao YX and Gu N: Clinicopathological and prognostic roles of STAT3
and its phosphorylation in glioma. Dis Markers. 2020:88338852020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song M, Wang C, Yang H, Chen Y, Feng X, Li
B and Fan H: P-STAT3 inhibition activates endoplasmic reticulum
stress-induced splenocyte apoptosis in chronic stress. Front
Physiol. 11:6802020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Wang Y, Shi Z, Liu J, Zheng S, Yang
J, Liu Y, Yang Y, Chang F and Yu W: Clinicopathological and
prognostic role of STAT3/p-STAT3 in breast cancer patients in
China: A meta-analysis. Sci Rep. 9:112432019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu HW, Lee PM, Bamodu OA, Su YK, Fong IH,
Yeh CT, Chien MH, Kan IH and Lin CM: Enhanced Hsa-miR-181d/p-STAT3
and Hsa-miR-181d/p-STAT5A ratios mediate the anticancer effect of
garcinol in STAT3/5A-Addicted glioblastoma. Cancers (Basel).
11:18882019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Susman S, Pirlog R, Leucuta D, Mitre AO,
Padurean VA, Melincovici C, Moldovan I, Crișan D and Florian SI:
The role of p-Stat3 Y705 immunohistochemistry in glioblastoma
prognosis. Diagn Pathol. 14:1242019. View Article : Google Scholar : PubMed/NCBI
|
